secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2025-08-29T23:59:59+00:00
Accession:  0001104659-25-085705
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 5.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma enters $5M subscription deal with Ocugen; Nasdaq deadline extended to Oct 21
--------------------------------------------------------------------------------

- Subscription agreement with Ocugen for $5M private placement as part of concurrent $25M financing.
- CEO Steven Kelly amended employment agreement with retention/transaction bonuses contingent on merger closing.
- Nasdaq extends bid price compliance deadline to Oct 21; must complete merger by Oct 7 and show $4 bid price.
- Merger with OrthoCellix must close by Oct 7 for continued listing on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925085705/0001104659-25-085705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925085705/tm2524685d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-085705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer